Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke

The discovery of immune checkpoint inhibitors (ICIs) such as programmed cell death protein 1 (PD-1) inhibitors, nivolumab and pembrolizumab, and programmed cell death ligand 1 (PD-L1) inhibitors, atezolizumab and durvalumab, has revolutionized the treatment of advanced non-small cell lung cancer (NS...

Descripción completa

Detalles Bibliográficos
Autores principales: Belluomini, Lorenzo, Fiorica, Francesco, Frassoldati, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360008/
https://www.ncbi.nlm.nih.gov/pubmed/32700194
http://dx.doi.org/10.1007/s40487-019-0092-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360008/
https://www.ncbi.nlm.nih.gov/pubmed/32700194
http://dx.doi.org/10.1007/s40487-019-0092-z

Ejemplares similares